A Phase 1 Single Dose PK Study in Adolescent Subjects With Fragile X Syndrome or Angelman Syndrome

Trial Profile

A Phase 1 Single Dose PK Study in Adolescent Subjects With Fragile X Syndrome or Angelman Syndrome

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Gaboxadol (Primary)
  • Indications Angelman syndrome; Fragile X syndrome
  • Focus Pharmacokinetics
  • Sponsors Ovid Therapeutics
  • Most Recent Events

    • 14 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 13 Jun 2017 According to an Ovid Therapeutics media release, the company expects topline data to be available in the second half of 2017.
    • 13 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top